Keywords

Animal Experimentation; Cardiac Imaging Techniques; Regenerative Medicine

Research group(s)

• Experimental and clinical cardiology
  Head: Mariann Pavone-Gyöngyösi
  Members:
  Martin Riesenhuber
  Mariann Pavone-Gyöngyösi
  Katrin Zlabinger

Research interests

My main research focus is the cardiac regenerative medicine, and associated basic research, using "omics" (transcriptomics, etc) technology, cell culture and imaging. My research includes experimental cardiac regeneration therapy with cell-based or cell-free or tissue engineered products. My team works on translational projects using experimental models of human cardiovascular diseases, such as different myocardial infarction models, conditioning of the heart, ventricular remodeling, and ischemic cardiomyopathies. Further applied research includes implantation of medical devices under experimental conditions, such as stents, closure devices (ASD, PFO, LAA), artificial heart valves, pacemakers, to evaluate the underlying histology and tissue reactions. I have a broad international scientific cooperation, performing several animal studies in the field of regenerative medicine.

Techniques, methods & infrastructure

Our lab has the facilities for molecular biology works, cell cultures, automated PCR, we use methods for preparation of samples for gene expressions and associated analyses. We have molecular imaging technology, fluorescent microscop and video microscopy to look at the cultivated cells subjected to different substances, eg. cells. secretome, miRNA. The other type of lab work includes the histology of explanted medical devices, such as stents, closure devices, valves, with paraffin or plastic embedding, staining and analyses, to understand the underlying pathology and tissue reaction. 

Our team perform large animal experiments with high translational value, simulating diverse human cardiovascular diseases, and involved in several European Commission projects, and other industry-sponsored trials.

Grants

• CresPace (2017)
  Source of Funding: EU, HORIZON2020
  Principal Investigator
• ReGenHeart (2017)
  Source of Funding: EU, HORIZON2020
  Principal Investigator
• SCIENCE - Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (project partner) (2015)
  Source of Funding: EU, H2020-PHC-2014
  Principal Investigator
• Fibro-Targets - Targeting cardiac fibrosis for heart failure treatment (project partner) (2013)
  Source of Funding: EU, FP7-HEALTH-2013-INNOVATION-1
  Principal Investigator
• Therapeutic and diagnostic miRNAs in cardioprotection (2013)
  Source of Funding: FWF (Austrian Science Fund), Joint Project
  Principal Investigator
• LifeValve - Living autologous heart valves for minimally invasive implantable procedures (project partner) (2009)
  Source of Funding: EU, FP7-HEALTH-2009
  Principal Investigator

Selected publications

1. Gyöngyösi, M. et al., 2016. Meta-Analyses of Human Cell-Based Cardiac Regeneration TherapiesResponse to Gyöngyösi, Wojakowski, Navarese, Moye, and the ACCRUE Investigators. Circ Res, 118(8), pp.1254-1263. Available at: http://dx.doi.org/10.1161/CIRCRESAHA.115.307347.
2. Gyongyosi, M. et al., 2015. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in Patients With Acute Myocardial Infarction Based on Individual Patient Data. Circulation Research, 116(8), pp.1346-1360. Available at: http://dx.doi.org/10.1161/CIRCRESAHA.116.304346.
3. Gyöngyösi, M. & Dib, N., 2011. Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease. Nature Reviews Cardiology, 8(7), pp.393-404. Available at: http://dx.doi.org/10.1038/nrcardio.2011.64.
4. Gyongyosi, M. et al., 2008. Serial Noninvasive In Vivo Positron Emission Tomographic Tracking of Percutaneously Intramyocardially Injected Autologous Porcine Mesenchymal Stem Cells Modified for Transgene Reporter Gene Expression. Circulation: Cardiovascular Imaging, 1(2), pp.94-103. Available at: http://dx.doi.org/10.1161/CIRCIMAGING.108.797449.
5. Gyöngyösi, M. et al., 2008. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med, 6(1), pp.70-81. Available at: http://dx.doi.org/10.1038/ncpcardio1388.